JPRN-UMIN000032257招募中未知
Phase I/II study of bi-weekly docetaxel and cisplatin plus S-1 (bi-weekly DCS) as first-line therapy for advanced esophageal cancer. - Phase I/II study of bi-weekly DCS as first-line therapy for advanced esophageal cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Synchronous or metachronous (within 5 years) double cancers, except for intoramucosal tumor curatively resected by local therapy 2)With active systemic infection disease 3)With active hepatitis B or C 4)With HIV infection 5)With a history of interstitial pneumonia, pulmonary fibrosis or irradiation pneumonitis 6)Severe psychological illness. 7)With continuous systemic steroid or immune-suppressive drug therapy. 8)Poorly controlled diabetes mellitus or thyroid diseases. 9)Unstable angina within 3 weeks or with a history of acute myocardial infarction within 3months 10)With history of hypersensitivity to docetaxel, cisplatin or polysorbate 80-containing formulations 11)Pregnant and/or nursing women or men who wish to have children in future 12)Judged to be unfit to participate in this study by investigator
研究者
相似试验
招募中
1 期
Phase I/II study of bi-weekly DCS as first-line therapy for advanced esophageal cancer.Esophageal cancerJPRN-jRCTs031180376Seto Yasuyuki38
已完成
1 期
Phase I/II study of biweekly docetaxel, cisplatin, and S-1 combination neoadjuvant chemotherapy in patients with stage III gastric cancergastric cancerJPRN-UMIN000011625Yokohama City University Medical Center51
已完成
1 期
Phase I/II trial of weekly docetaxel and concomitant radiotherapy for unresectable esophageal squamous cell carcinoma after induction chemothrapynresectable esophageal squamous cell carcinoma after induction chemotherapyJPRN-UMIN000004856Gastroenterologic surgery, Kanazawa university44
未知
2 期
A phase II study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.advanced gastric cancerJPRN-UMIN000000801Dept. of Internal Medicine(4)30
已完成
2 期
A phase II randomized study of DP(Docetaxel+Cisplatin),DJ(Docetaxel+Carboplatin),and TJ(Paclitaxel+Carboplatin) in patients with advanced and recurrent endometrial carcinomaadvanced or recurrent endometrial carcinomaJPRN-C000000170Japanese Gynecologic Oncology Group90